DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03233178

ALT

Completed

Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

4,000

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•ALT, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03233178
Org study IDALT

Timeline

Milestones

Study first posted2017-07-28actual
Last update posted2017-07-28actual
Study start2017-01actual (month precision)
Primary completion2017-06actual (month precision)
Study completion2017-06actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

This study will include patients with T2DM who are patients at LMC Diabetes \& Endocrinology. Patients will be included in the treatment cohorts if they initiated canagliflozin, dapagliflozin, liraglutide or sitagliptin, between January 2011 and December 2015, and did not discontinue the treatment prior to 6 weeks of being on the medication. The control group will include patients with T2DM who are patients at LMC Diabetes \& Endocrinology, and who did not initiate any new diabetes treatment between June 2014 and June 2015.

Inclusion criteria

•Diagnosis of T2DM based upon historical clinical diagnosis
•Patients who initiated canagliflozin, dapagliflozin, liraglutide or sitagliptin by an LMC physician between January 2011 and December 2015, or patients who did not initiate a new diabetes therapy between June 2014 and June 2015.

Exclusion criteria

•Diagnosis of type 1 diabetes
•Patients who switched to one of the study treatments from another medication of the same medication class

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Glycemic / diabetes
2
MASH / liver
1
Cardiometabolic biomarkers
1

Weight & body composition

3 endpoints
Secondary/protocol endpoint

Change in body weight from baseline to follow-up

Time frame:1 year

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI) from baseline to follow-up

Time frame:1 year

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Waist Circumference (WC) from baseline to follow-up

Time frame:1 year

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Change in Hemoglobin A1c from baseline to follow-up

Time frame:1 year

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Fasting Plasma Glucose from baseline to follow-up

Time frame:1 year

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

MASH / liver

1 endpoint
Primary/protocol endpoint

Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control

Time frame:1 year

ALT, change

change from baseline, improvement

LOINC 1742-6

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Change in triglycerides from baseline to follow-up

Time frame:1 year

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.